Crossmark

Approvals in 2016: cost–benefit challenges of new anticancer agents

Crossref DOI link: https://doi.org/10.1038/nrclinonc.2017.12

Published Online: 2017-03-01

Published Print: 2017-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Savage, Philip
License Information

Text and Data Mining valid from 2017-03-01
More Information

Article History

First Online: 1 March 2017

Competing interests

: The author declares no competing financial interests.